You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Respiratory
Enhertu Showed Clinically Meaningful and Durable Responses Across Multiple HER2 Expressing Tumor Types in DESTINY-PanTumor02 Phase 2 Trial
Login
Username:

Password:


Related Headlines

bioMérieux launches PCR wastewater test to support early detection of infectious disease outbreaks

Clario partners with AWS on advancing clinical data analysis with generative AI

Zynext Ventures invests in Feldan Therapeutics

Sanofi advances respiratory pipeline with positive amlitelimab data and expanded clinical programmes

Sichuan Kelun-Biotech reveals sacituzumab tirumotecan (sac-TMT) clinical studies results

Amgen's IMDELLTRA shows superior overall survival in small cell lung cancer trial

VARON expands access to home oxygen concentrators

SciTech Development secures second FDA clearance for ST-001 in early-stage cancer trials

European Commission approves subcutaneous RYBREVANT with ENHANZE for advanced EGFR-mutated lung cancer

Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval

Dupixent receives approval in Japan as first biologic for COPD treatment

Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA

Actinium Pharmaceuticals signs Ac-225 radioisotope agreement with Eckert & Ziegler

GSK's Nucala (Mepolizumab) COPD application accepted by EMA

Everest Medicines' EVM14 IND application receives US FDA approval

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2025